health pharma news today obesity drugs glp-1 today A new oral option is now part of medicine. FDA approved Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist, for adults with obesity or overweight with at least one weight-related World Health Leaders | FDA

A specific, sensitive, and rapid method for the determination of glutathione and its application in ocular tissues

Biochem Biophys Res Commun 497:207213

What reaches circulation is highly variable

A., Matot, E., Malka, G., Kosower, N., Rein, M., Zilberman-Schapira, G., Dohnalov, L., Pevsner-Fischer, M., Bikovsky, R., Halpern, Z., Elinav, E., & Segal, E

Among those who tolerate and stay on GLP 1 therapy, observational studies show consistent improvements in weight related quality of life, physical functioning, and emotional health over 612 months

Administered via intramuscular injection, it ensures sustained energy levels and improved work output